SCHEMBL21564784

SCHEMBL21564784

CCOC(=O)/C=C/c1cn(-c2ccc(S(C)(=O)=O)cc2)c(=O)c(N2CCOCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.43
AKR1C3 P42330 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS2 P35354 1/20 0.40
MAPT P10636 6/20 0.40
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
KDM4E B2RXH2 2/20 0.38
HTT P42858 1/20 0.38
PAX8 Q06710 1/20 0.38
AKT1 P31749 1/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258619 0.88 MAPT (0.43) KMT2AMAPTKDM4EHTTAKT1
SCHEMBL21564606 0.87 PTGS2 (0.40) MTORPTGS2ALDH1A1PKM
SCHEMBL21564807 0.84 MTOR (0.43) MTORLMNA
SCHEMBL21564613 0.81 POLB (0.38) MEN1KMT2AMAPTGAAL3MBTL1
SCHEMBL21553130 0.80 F13A1 (0.37) MEN1KMT2AMAPTGAAL3MBTL1
SCHEMBL21564617 0.80 MTOR (0.44) MTORAKR1C3MEN1KMT2APTGS2
SCHEMBL21564614 0.79 ALDH1A1 (0.39) MEN1KMT2AMAPTALDH1A1
SCHEMBL21564467 0.79 CNR1 (0.43) MEN1KMT2AMAPTL3MBTL1LMNA
SCHEMBL21553097 0.76 IDO1 (0.40) MEN1KMT2AMAPTGAAHTT
SCHEMBL21564785 0.75 GABRA2 (0.38) MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A MTOR 4241/4885AKR1C3 3166/4885MEN1 3684/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A MTOR 4069/4885AKR1C3 2781/4885MEN1 3213/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A MTOR 4241/4885AKR1C3 3166/4885MEN1 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.